IRONWOOD PHARMACEUTICALS, INC. Cost of Revenue
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Cost of Revenue of $3.14 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-16.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2023-02-16
- IRONWOOD PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2020-12-31 was $897.00K, a 91.86% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2020-03-31 was $2.24M, a 114.67% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2020 was $3.14M, a 86.86% decline from fiscal 2019.
- IRONWOOD PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2019 was $23.88M, a 27.10% decline from fiscal 2018.
- IRONWOOD PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2018 was $32.75M, a 71.50% increase from fiscal 2017.
- IRONWOOD PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2017 was $19.10M, a 922.32% increase from fiscal 2016.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2020-12-31 | $897.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $897.00K derived: sum of 2 quarters · filed 2023-02-16 | $897.00K derived: sum of 3 quarters · filed 2023-02-16 | $3.14M 10-K · filed 2023-02-16 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $2.24M 10-Q · filed 2021-11-04 | $13.25M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.24M 10-Q · filed 2021-08-05 | $13.25M derived: sum of 3 quarters · filed 2022-02-18 | $13.76M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $2.24M 10-Q · filed 2021-05-06 | $13.25M derived: sum of 2 quarters · filed 2022-02-18 | $13.76M derived: sum of 3 quarters · filed 2022-02-18 | $25.07M derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $11.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $11.52M derived: sum of 2 quarters · filed 2022-02-18 | $22.83M derived: sum of 3 quarters · filed 2022-02-18 | $23.88M 10-K · filed 2022-02-18 |
| 2019-09-30 | $506.00K 10-Q · filed 2020-11-05 | $11.82M derived: sum of 2 quarters · filed 2020-11-05 | $12.86M 10-Q · filed 2020-11-05 | $34.33M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-06-30 | $11.31M 10-Q · filed 2020-08-06 | $12.36M 10-Q · filed 2020-08-06 | $33.82M derived: sum of 3 quarters · filed 2021-02-17 | $38.44M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-03-31 | $1.04M 10-Q · filed 2020-05-06 | $22.51M derived: sum of 2 quarters · filed 2021-02-17 | $27.12M derived: sum of 3 quarters · filed 2021-02-17 | $31.19M derived: sum of 4 quarters · filed 2021-02-17 |
| 2018-12-31 | $21.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $26.08M derived: sum of 2 quarters · filed 2021-02-17 | $30.14M derived: sum of 3 quarters · filed 2021-02-17 | $32.75M 10-K · filed 2021-02-17 |
| 2018-09-30 | $4.62M 10-Q · filed 2019-10-31 | $8.68M derived: sum of 2 quarters · filed 2019-10-31 | $11.29M 10-Q · filed 2019-10-31 | $20.27M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $4.07M 10-Q · filed 2019-07-30 | $6.67M 10-Q · filed 2019-07-30 | $15.66M derived: sum of 3 quarters · filed 2020-02-13 | $21.74M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $2.61M 10-Q · filed 2019-05-02 | $11.59M derived: sum of 2 quarters · filed 2020-02-13 | $17.67M derived: sum of 3 quarters · filed 2020-02-13 | $21.17M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $8.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $15.06M derived: sum of 2 quarters · filed 2020-02-13 | $18.57M derived: sum of 3 quarters · filed 2020-02-13 | $19.10M 10-K · filed 2020-02-13 |
| 2017-09-30 | $6.08M 10-Q · filed 2018-11-06 | $9.58M derived: sum of 2 quarters · filed 2018-11-06 | $10.11M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $3.50M 10-Q · filed 2018-08-06 | $4.03M 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | $531.00K 10-Q · filed 2018-05-04 | |||
| 2016-12-31 | $1.87M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |